Search Results 1731-1740 of 19643 for Hemoglobin

1. Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma - Mayo Clinic

   Hemoglobin \> = 10.0 g/dL 4. Creatinine clearance \>= 60 mL/min calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine ...

2. Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Mayo Clinic

   - Hemoglobin < 10 g/dL (within 30 days of randomization). - Leukocytes < 3,000/microliter (within 30 days of randomization). - Platelets < 100,000 ...

3. MMRC Horizon One Adaptive Platform Trial Evaluating Therapies In RRMM - Mayo Clinic

   ... hemoglobin ≥ 8 g/dL (transfusion and/or growth factor support is allowed for hematologic parameters as long as the investigator deems the participant ...

4. Phase 2 Study of JK07 in Chronic Heart Failure - Mayo Clinic

   Screening hemoglobin ≥ 9.0 g/dL. Exclusion Criteria: Uncontrolled hypertension. Sustained systolic Blood Pressure (BP) < 90 mmHg and/or diastolic BP < 50 ...

5. A Study of Lutetium Lu 177 Dotatate (Lutathera®) in Patients with Inoperable, Progressive Meningioma after External Beam Radiation Therapy - Mayo Clinic

   * Hemoglobin \>= 9.0 g/dL (obtained =\< 14 days prior to registration) * Direct bilirubin \< 1.5 x upper limit of normal (ULN) (or total bilirubin =\< 3.0 x ...

6. A Study of Cediranib and Olaparib Combined, Compared to Either Drug Alone, or to a Standard Chemotherapy in Treating Patients who have a Return of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Mayo Clinic

   Hemoglobin >= 10 g/dL; Total bilirubin within =< 1.5 times the upper limit of normal (ULN) institutional limits; Aspartate aminotransferase (AST) (serum ...

7. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

   hemoglobin ≥ 9 g/dL (may have been transfused);; alanine aminotransferase (ALT, SGPT) ≤ 3.5 x upper limit of normal (ULN);; aspartate aminotransferase (AST ...

8. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor - Mayo Clinic

   Hemoglobin ≥ 9 g/dL;; Absolute neutrophil count ≥ 1.5 × 109/L;; Platelet count ≥ 100 × 109/L;; ALT and AST ≤ 2.5 × upper limit of normal (ULN), with the ...

9. Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies - Mayo Clinic

   Hemoglobin ≥9.0 g/dL; ANC ≥1.5 x 109/L; Platelet count ≥75 x109/L. Note: For Expansion Cohort 13 (hepatocellular cancer), the platelet count requirement is ...

10. A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients - Mayo Clinic

    Hemoglobin ≥ 11 g/dL;; Platelet count ≥ 100,000 cells/mm^3;; Absolute neutrophil count ≥ 1500 cells/mm^3;; Calculated creatinine clearance ≥ 30 mL/min ...